Forward P/S Multiple: Helius Medical Technologies, Inc. (HSDT)
Helius Medical (HSDT) develops unique neuromodulators for multiple sclerosis therapy, leveraging a streamlined distribution network to maintain stable margins. The forward P/S metric demonstrates a fundamental valuation trend relative to future sales, with the value fixed at 7.30. Business growth is driven by the expansion of insurance reimbursements in the US, rendering the company independent of general macroeconomic fluctuations.
Summary analytical data breakdowns for heliusmedical.com (HSDT)
- market price and analyst price targets:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- debt and liquidity data:
Total Debt to Capital Helius Medical|HSDT - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Helius Medical Technologies|HSDT - Company Aggregate Debts|Debt to Book Capitalization Ratio Helius Medical Technologies, Inc.|HSDT - Company Long-Term Debt|Company Short-Term Debts Helius Medical Technologies|Quick Liquidity heliusmedical.com
- financial results and valuation multiples details:
HSDT - Net Financial Result|Projected Future Earnings Helius Medical|HSDT - Price to Earnings Multiple|Projected Price to Earnings Helius Medical Technologies|HSDT - Company Value to Earnings Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Helius Medical Technologies, Inc.|HSDT - Operating profit before amortization|Net earnings per share (EPS TTM) Helius Medical Technologies|HSDT - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months heliusmedical.com|HSDT - Earnings growth in current year|Net earnings per share growth forecast for next year Helius Medical
- sales and revenue indicators:
Fundamental company analysis:HSDT (Helius Medical Technologies Inc.)
The metric is calculated as the ratio of current market capitalization to expected sales volume, allowing for a real-time assessment of asset overvaluation prior to the publication of reports. An analysis of the forward price-to-sales ratio reveals the degree of market optimism amid the complexities of insurance reimbursements and competition from pharmacotherapy, where any sharp spike in the curve signals inflated expectations for the neuromodulation technologies of Helius Medical (HSDT).
Who Helius Medical competes with
Price-to-Projected Revenue Ratio Biogen BIIB|NBIX - Forward Price-to-Revenue Multiple|Regencell - Forward P/S Multiple|Market Cap to Future Revenue Ratio Axsome Corp|ACAD: Forward P/S Multiple|Market Cap to Projected Revenue XENE|VKTX (Viking Therapeutics, Inc.) - Forward P/S Multiple|Supernus Pharmaceuticals, Inc. (SUPN) - Market Cap to Expected Sales Ratio|Forward P/S Multiple CPRX|Forward Price-to-Revenue Multiple Denali Corp DNLI|Forward P/S Multiple HRMY (Harmony Biosciences)|Forward P/S Multiple biohavenpharma.com BHVN|AMLX - Price-to-Projected Revenue Ratio|TRVI: Price-to-Projected Revenue Ratio|PRAX: Forward P/S Multiple|Anavex Life Sciences Corp - Forward Price to Sales|Price-to-Projected Revenue Ratio CeriBell, Inc.|Prothena Corporation (PRTA) - Market Cap to Expected Sales Ratio|Forward P/S Multiple ALEC|Annexon Biosciences - Market Cap to Projected Revenue|Omeros - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio NGNE (Neurogene Therapeutics)|ACIU - Price-to-Projected Revenue Ratio|VYGR (voyagertherapeutics.com) - Market Cap to Projected Revenue|NMRA: Forward P/S Multiple|Market Cap to Future Revenue Ratio Scilex Holding (SCLX)|Forward Price-to-Revenue Multiple TVGN|Forward P/S Multiple Alpha Cognition Corp|Price-to-Projected Revenue Ratio Cognition Therapeutics (CGTX)|IKT (inhibikase.com) - Forward Price to Sales|Price-to-Projected Revenue Ratio Cassava Sciences SAVA|Assertio Holdings (ASRT) - Market Cap to Future Revenue Ratio|Coya - Forward P/S Multiple|Forward Price to Sales VTGN (Vistagen Therapeutics)|OVID: Forward P/S Multiple|Market Cap to Future Revenue Ratio acumenpharm.com (ABOS)|Price-to-Projected Revenue Ratio CervoMed|Price-to-Projected Revenue Ratio ATHE|Forward P/S Multiple CLNN|Market Cap to Expected Sales Ratio pepgen.com|Jupiter Neurosciences Inc - Forward Price-to-Revenue Multiple|Forward P/S Multiple relmada.com RLMD|ANVS - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Grace Therapeutics, Inc. GRCE|AIFF (Firefly Neuroscience Inc) - Forward Price-to-Revenue Multiple|Klotho Neurosciences - Forward Price to Sales|Price-to-Projected Revenue Ratio NeuroSense Therapeutics Ltd|Forward Price-to-Revenue Multiple revivapharma.com (RVPH)|Forward P/S Multiple MTVA|NRXS - Market Cap to Future Revenue Ratio|Forward P/S Multiple PASG (Passage Bio)|NEUP: Market Cap to Projected Revenue|Minerva Neurosciences - Forward P/S Multiple|Market Cap to Expected Sales Ratio athira.com ATHA|ADXN: Forward P/S Multiple|Forward Price-to-Revenue Multiple Alzamend Neuro|CYCN (Cyclerion Therapeutics Inc.) - Forward P/S Multiple|Forward P/S Multiple Protagenic|Price-to-Projected Revenue Ratio Pasithea Therapeutics (KTTA)|Price-to-Projected Revenue Ratio CRGT (cortigent.com)|Forward P/S Multiple ATXI (Avenue Therapeutics, Inc.)|Forward Price to Sales BCLI|CARA - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Chromocell CHRO|ELYM: Forward P/S Multiple|Market Cap to Projected Revenue ITCI|Forward Price-to-Revenue Multiple LBPH|MRNS (Marinus Pharmaceuticals Inc) - Price to Expected Revenue Ratio|Price-to-Projected Revenue Ratio NKGen (NKGN)|NeuroBo Pharma - Market Cap to Projected Revenue|Forward P/S Multiple SAGE (Sage Therapeutics, Inc.)|synaptogen.com (SNPX) - Market Cap to Future Revenue Ratio|TRVN: Forward Price-to-Revenue Multiple|VIGL - Forward P/S Multiple|Anew Medical (WENA) - Price-to-Projected Revenue Ratio|Cerevel Corp - Forward Price to Sales
